title: [Is the "polypill" in cardiovascular prevention an option].
authors.affiliation: Cochrane Schweiz, Institut universitaire de médecine sociale et préventive, Lausanne.
authors.forename: Aline
authors.initials: A
authors.lastname: Flatz
authors.affiliation: Service de biomédecine, Division de pharmacologie clinique, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne.
authors.forename: Delphine
authors.initials: D
authors.lastname: Renard
authors.affiliation: Cochrane Schweiz, Institut universitaire de médecine sociale et préventive, Lausanne.
authors.forename: Erik
authors.initials: E
authors.lastname: von Elm
mesh_terms: D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004338:Drug Combinations; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D004338:Drug Combinations